Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Mold-Tek Packaging Ltd

| Q2 FY26 Earnings Conference Call

NEUTRAL SENTIMENT

Report Source

⬤29th Oct 25

Summary : Mold-Tek Packaging reported decent Q2 FY26 growth, driven by pharma and food/FMCG, despite seasonal and GST-related headwinds, with strong future expansion plans.

Management Perspective positive : I am very glad to inform you we have a decent growth in volumes.Most heartening and very good indicator for me is the growth in pharma packaging sales.I am very confident because already our food and FMCG production started in Panipat.The future looks bright and better utilization as the rains subside and demand picks up.

Concall Report Analysis & Insights

Business Overview

  1. Q2 FY26 saw 7% volume growth and 9.65% sales value increase.
  2. H1 EBITDA margin improved to Rs. 40.6 per kg from Rs. 36.73 last year.
  3. Pharma packaging sales grew significantly by 45% in Q2, reaching over Rs. 10 crores.
  4. Food and FMCG segments also registered decent growth.
  5. Overall capacity utilization dipped to 63% in Q2 from 74% in Q1.

Future Growth Prospects

  1. Panipat operations will sustain food and FMCG growth, with new contracts signed.
  2. Pharma revenue targeted at Rs. 35+ crores this year, Rs. 55-60 crores next year.
  3. New IML integration at Sultanpur is expected to reduce production costs from Q3-Q4.
  4. Greenfield pharma expansion on acquired land is planned for FY27.
  5. New pharma clients are onboarding, adding commercial orders from Q4.

Management Insights

  1. Q2 and Q3 are typically low-volume seasons due to rains and holidays.
  2. Pharma packaging sales grew 45% in Q2, exceeding Rs. 10 crores.
  3. Confident in achieving 10% volume growth for the full year, driven by Q4.
  4. Expect to maintain 40+ EBITDA per kg in the second half of the year.
  5. Panipat plant will add Rs. 4-5 crores turnover next financial year from one client.

Signs of Skepticism

  1. Management clarified pharma revenue guidance, stating they never said Rs. 90 crores for the current year.
  2. Initial 12-15% volume growth guidance is maintained at 12% despite Q2 slowdown, relying on Q4 pickup.

Risk Factors

  1. GST implementation caused a temporary lull in September sales and dispatches.
  2. Heavy monsoon impacted paint and lubricant segment demand in Q2.
  3. Competition in food and FMCG is pressuring realizations per kg.
  4. Lower capacity utilization in Q2 affected EBITDA margins.
  5. Lubricant consumption growth may lag despite economic movement.

Good To Know

  1. IML operations consolidated at Sultanpur for efficiency, including in-house HTL label manufacturing.
  2. Current year CAPEX expected to be around Rs. 100-105 crores, down from Rs. 130-140 crores.
  3. Maintenance CAPEX is approximately Rs. 35-40 crores annually.
  4. Over 50 pharma companies visited, with 20-25 now active buyers in small quantities.
  5. Actions taken against patent infringement involve stopping production and seizing molds of infringing companies.

Key Drivers

  1. Pharma segment shows strong growth.
  2. Panipat plant boosts North sales.
  3. IML integration cuts production costs.
  4. GST reduction to drive demand.

Key Analyst Discussions

Competitive Environment

  1. Competition in food and FMCG affecting realizations per kg.
  2. Growth contribution from Asian Paints and Grasim (Birla Opus) in paint segment.
  3. Slowdown in paint demand across players, except for Birla Opus.
  4. Impact of new small-time players in food and FMCG sector.

Market Trends & Consumer Behavior

  1. Impact of heavy rains and cyclones on paint and lubricant demand.
  2. Seasonal low-volume periods in Q2 and Q3.
  3. Effect of festive season on sweet pack demand.
  4. Overall market demand for pharma packaging in the country.

Financial Highlights

  1. Impact of GST implementation on Q2 dispatches and volume growth.
  2. Reasons for Q2 EBITDA per kg decline and outlook for H2.
  3. Paint segment growth decline in Q2 compared to Q1.
  4. Pharma revenue targets and growth trajectory for current and next fiscal years.
  5. Expected cost reduction benefits from IML integration.

Product Composition

  1. Shift in product mix towards higher-value food and pharma segments.
  2. Specific products driving pharma growth (EV tubes, caps, bottles, canisters).
  3. Traction and margins from the sweet pack segment.
  4. Volume-value mix of IML and non-IML products.

Strategic Considerations

  1. Capacity utilization and expansion plans for Panipat F&F plant.
  2. Update on new pharma client onboarding and trial stages.
  3. Guidance on future CAPEX and greenfield expansion for pharma.
  4. Strategy to address time delays and freight costs from centralized operations.
Mold-Tek Packaging Ltd (MOLDTKPAC) Concall Report Analysis & Insights | Dhanarthi